Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer

Chin Med J (Engl). 2020 Nov 5;133(21):2630-2632. doi: 10.1097/CM9.0000000000001120.
No abstract available

MeSH terms

  • Apoptosis
  • B7-H1 Antigen / genetics
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Cost-Benefit Analysis
  • Humans
  • Immune Checkpoint Inhibitors
  • Immunotherapy
  • Ligands
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics

Substances

  • B7-H1 Antigen
  • Immune Checkpoint Inhibitors
  • Ligands